After 63 Years, This Legendary Mexican Restaurant In San Antonio Is Being Forced To Close
San Antonio's culinary scene is rich with history and unforgettable flavors, attracting locals and tourists alike with food unparalleled anywhere else in the world. But post-pandemic, the restaurant scene never fully recovered from the hits that it took, equally losing customer sales and employee retention rates. Just days after the beloved, similarly-iconic Denver-based Breakfast Inn announced it was closing its doors for good, San Antonio's legendary Mexican restaurant, Oscar's Taco House, dropped the bomb that it's unexpectedly shutting down permanently -- but not by choice.
According to multiple reports from local news sources, Oscar's Taco House is being forced to close by the city to make way for a new bridge. The bridge is part of a five-year project, officially named the South Zarzamora Street Overpass at Union Pacific Railroad, and it is expected to construct new bridges, roads, and sidewalks to improve mobility of the Southwest Side neighborhood. The restaurant's owner, Alex Pruneda, told local news source MySA that the city wanted the building closed by May 15, 2025, but Pruneda wrote a letter begging for an extension to give his 32 employees more time to prepare. The restaurant is set to officially lock up for the last time on June 28.
Read more: 11 Mexican Restaurant Chains, Ranked Worst To Best
Oscar G. Garcia opened Oscar's Taco House in 1962 at 705 Barrett Place, San Antonio, operating it first as a carhop burger joint and soon adding classic Tex-Mex entrees (if you're curious, here's what makes Tex-Mex different from Mexican cuisine). Garcia's sons took over the restaurant in 1978 after he passed away, but maintained the classic, old-school feel of decor and service. Over 40 years later, the restaurant was purchased in 2021 by close family friend Alex Pruneda, who's continued serving burgers, enchiladas, and, of course, San Antonio's world-famous and unique puffy tacos ever since.
In the midst of Oscar's Taco House ceasing operations, lifelong fans and devoted customers expressed their disappointment on social media. In a Facebook group for San Antonio Restaurants, people shared stories about decades of happy memories within the restaurant's walls. One commenter said "I never thought [this] would happen. I hope they relocate, [because] that's a fav in that area," while another agreed that "it will be missed by customers who called [it] home." Oscar's Taco House has no current plans to relocate, so in the meantime, San Antonians will have to visit one final time before the end of June and take a chance on some of the other absolute best restaurants in San Antonio.
Read the original article on Tasting Table.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
17 minutes ago
- Business Upturn
HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech
MIRAMAR, Fla., June 04, 2025 (GLOBE NEWSWIRE) — HCW Biologics Inc. ('HCWB' or 'HCW Biologics'), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, and WY Biotech Co., Ltd., a China-based company specializing in the early-stage development of recombinant protein drugs and gene/cell therapies, announced today that WY Biotech has completed its due diligence related to HCWB's technology transfer report, including the characterization of the cell line, delivered on May 13, 2025. In addition, WY Biotech confirmed its commitment to proceed with the development and commercialization of the licensed molecule, HCW11-006, for in vivo therapeutic applications. The Agreement is now fully binding and HCW Biologics has earned the $7.0 million upfront license fee under the terms of the Agreement, as amended. In addition to the $7.0 million upfront payment, HCWB is eligible to receive additional significant development milestone payments and double-digit royalties on future product sales. Furthermore, HCWB will share a substantial portion of the proceeds from a future transaction(s) involving the molecule, if such a transaction occurs. HCWB also has a payment-free, milestone-free, and royalty-free option to recapture the development and commercialization rights of this molecule for the United States, Canada, Central America, and South America (Opt-in Territory) after the conclusion of the Phase 1 clinical trial. WY Biotech is financially responsible for all costs associated with research and development, manufacturing, clinical development, regulatory approval, and commercialization for the molecule. HCWB will be responsible for costs associated with clinical development, regulatory approval, and commercialization in the Opt-in Territory, if HCWB exercises its opt-in rights. Both companies will work cooperatively in the development stage with a global focus for clinical development and partnering. Dr. Hing C. Wong, Founder and Chief Executive Officer of HCW Biologics, stated, 'We have a strategic focus to establish commercialization partnerships for our novel protein and antibody therapies with innovative leaders in the immunotherapy field. HCW11-006, the product candidate subject to the license with WY Biotech, combines several different immune functional domains on HCW Biologics' TRBC drug discovery and development platform as part of a group of compounds characterized as Multi-Functional Immune Cell Stimulators. Preclinical studies demonstrated that HCW11-006 is highly effective at inducing anti-tumor CD8+ T cell and NK cell responses without triggering unwanted side effects in relevant solid tumor animal models.' About HCW Biologics: HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases. The Company's immunotherapeutics represent a new class of drug that it believes have the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation — and in doing so, improve patients' quality of life and possibly extend longevity. Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to senescence-associated diseases and conditions that diminish healthspan, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as indications that impact quality-of-life that are not life-threatening. The Company's lead product candidate, HCW9302, was developed using the Company's legacy TOBI™ (Tissue factOr-Based fusIon) platform. The Company has created another drug discovery technology, the TRBC platform, which is not based on Tissue Factor. The TRBC platform has the capability to construct immunotherapeutics that not only activate and target immune responses but are also equipped with receptors that specifically target cancerous or infected cells. This platform is a versatile scaffold that enables the creation of multiple classes of immunotherapeutic compounds: Class I: Multi-Functional Immune Cell Stimulators; Class II: Second-Generation Immune Checkpoint Inhibitors; Class III: Multi-Specific Targeting Fusions and Enhanced Immune Cell Engagers. These novel immunotherapeutics can be used to treat a wide range of disease indications, including oncology, autoimmune diseases, and improving quality of life conditions. The Company has constructed over 50 molecules using the TRBC platform, including HCW11-002, HCW11-018 and HCW11-040. Further preclinical evaluation studies are currently being conducted for these three molecules the Company has selected based on promising early data. The Company has two licensing programs in which it has licensed exclusive rights for some of its proprietary molecules. See the Company Pipeline at Forward Looking Statements: Statements in this press release contain 'forward-looking statements' that are subject to substantial risks and uncertainties. These statements are made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'expect,' 'believe,' 'will,' 'may,' 'should,' 'estimate,' 'project,' 'outlook,' 'forecast' or other similar words and include, the potential for a future transaction and sharing proceeds therefrom; the ability for HCWB to recapture and commercialize rights in certain territories; the ability of HCW11-006 to induce anti-tumor CD8+ T cell and NK cell responses; . Forward-looking statements are based on the Company's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled 'Risk Factors' in the annual report on Form 10-K filed with the United States Securities and Exchange Commission (the 'SEC') on March 28, 2025, the latest Form 10-Q filed with the SEC on May 15, 2025 and in other filings filed from time to time with the SEC. Company Contact: Lee FlowersSenior Vice President, Business DevelopmentHCW Biologics Inc. [email protected]
Yahoo
19 minutes ago
- Yahoo
Restaurant known for tacos now on Tacoma Mall's store directory as ‘Coming Soon'
A restaurant specializing in tacos is adding another location in Tacoma. Taco Street is now listed on the Tacoma Mall's merchant page as 'Coming Soon.' Its location is in the Food Court across from The Drop. Taco Street also operates at the Waterfront Market at Point Ruston, 5101 Yacht Club Road. Elonka Perez is executive chef, owner and founder of Taco Street. Perez told The News Tribune in May in response to questions that the brand was 'planning a new location in Tacoma. Timing is closer to August/September.' Taco Street is among several new merchants joining the mall's roster this year, including Seoul Bowl (also in the Food Court), Pop Mart and Lovesac (in the upcoming mall Village). New York-based Gregorys Coffee opened its first Pierce County location at the mall this spring. The mall continues work on its new Village concept outside the main building and is set to open later this fall. The Village will include Dave's Hot Chicken, Shake Shack, Supreme Dumplings, Simply Thai restaurant, Happy Lamb Hot Pot and Gong Cha bubble tea. In May, a notice on Taco Street's website said that the brand's Seattle location, in operation for eight years, would transform into a commissary kitchen 'effective immediately.' The restaurant's announcement cited issues with parking, staff safety and rising costs that 'made it unsustainable to keep operating as a quick-service restaurant.' The notice added, 'While the doors may be closing to regular public service, we will still be offering catering and private event hosting upon request.' As for a second Tacoma location, the notice stated, 'With change, comes new opportunity! We are thrilled to announce that we will be opening a new location in Tacoma this fall.'
Yahoo
19 minutes ago
- Yahoo
Inter Milan Ready To Sacrifice Germany Star This Summer As Big Changes Expected In Transfer Market
Inter Milan Ready To Sacrifice Germany Star This Summer As Big Changes Expected In Transfer Market Inter Milan are ready to sacrifice defender Yann Bisseck this summer as they prepare for big changes in the transfer market this summer. This according to today's print edition of Rome-based newspaper Corriere della Sera, via FCInterNews. Advertisement Inter Milan have just lost the Champions League final in absolutely humiliating fashion to Paris Saint-Germain. However, the Nerazzurri can hardly afford to just wait around and lick their wounds. They must react and start planning for next season. Inter Milan Ready To Sacrifice Yann Bisseck As Big Summer Changes Expected MILAN, ITALY – APRIL 23: Meanwhile, Yann Aurel Bisseck of FC Internazionale looks on. Meanwhile, during the warm up prior to the coppa Italia Semi Final match between FC Internazionale and AC Milan at Stadio Giuseppe Meazza on April 23, 2025 in Milan, Italy. (Photo by) In defense, the Corriere della Sera reports, there could be quite the overhaul. Inter Milan will have plenty of cash to invest in the market this summer. The massive revenues they've brought in from the Champions League make sure of that. However, the Nerazzurri could still make a big sale to further fund incoming deals. Advertisement According to the Corriere della Sera, defender Yann Bisseck is one player Inter will listen to offers for. The likes of Manchester United and West Ham United are reportedly interested in the 24-year-old. Meanwhile, the Corrirere della Sera report, midfielders Davide Frattesi and Kristjan Asllani could depart. And Genoa's Morten Frendrup would be near the top of the list of targets to replace them. In addition, the Corriere della Sera anticipates, there will also be signings in attack. Ange-Yoan Bonny, Joshua Zirkzee, and Rasmus Hojlund are major targets in this respect.
